Company Interview / Rhythm hits high note with strategic new deal

Rhythm Biosciences (ASX: RHY) has acquired the Genetype genetic risk assessment business assets in a $625,000 transaction finalized today. The acquisition integrates Genetype's genetic risk assessment technology with Rhythm's blood-based cancer diagnostics, creating a dual-technology platform for early cancer detection.

According to CEO Dr. David Atkins, this strategic move positions Rhythm to expand its capabilities in preventive healthcare while leveraging immediate revenue from Genetype's existing commercial products.

The acquisition also broadens Rhythm's presence in the US market and ensures business continuity with eight key Genetype team members joining the company.